Aeglea Bio Therapeutics Inc (AGLE) Given Consensus Recommendation of “Strong Buy” by Brokerages

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a one year consensus price target of $24.00 for the company and are forecasting that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Aeglea Bio Therapeutics an industry rank of 158 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a report on Friday, November 10th.

Shares of Aeglea Bio Therapeutics (AGLE) traded down $0.17 during trading hours on Friday, hitting $5.52. The company had a trading volume of 52,706 shares, compared to its average volume of 42,575. Aeglea Bio Therapeutics has a twelve month low of $2.81 and a twelve month high of $8.14. The stock has a market capitalization of $96.54 and a price-to-earnings ratio of -3.02.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.07. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. The business had revenue of $1.26 million during the quarter. equities analysts anticipate that Aeglea Bio Therapeutics will post -1.97 EPS for the current year.

In other news, Director Anthony G. Quinn acquired 7,956 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was acquired at an average cost of $4.98 per share, for a total transaction of $39,620.88. Following the completion of the acquisition, the director now owns 14,100 shares in the company, valued at $70,218. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Charles N. York II acquired 6,500 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were purchased at an average price of $4.59 per share, with a total value of $29,835.00. Following the completion of the acquisition, the chief financial officer now owns 10,828 shares of the company’s stock, valued at approximately $49,700.52. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 57,691 shares of company stock valued at $269,483. 27.00% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in Aeglea Bio Therapeutics stock. Vanguard Group Inc. grew its holdings in Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) by 9.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 150,774 shares of the biotechnology company’s stock after purchasing an additional 12,966 shares during the quarter. Vanguard Group Inc. owned about 1.12% of Aeglea Bio Therapeutics worth $579,000 as of its most recent filing with the SEC. 46.89% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply